EE219 Lorlatinib as a First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer: A Cost-Effectiveness Analysis in Greece
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.487
https://www.valueinhealthjournal.com/article/S1098-3015(23)03617-3/fulltext
Title :
EE219 Lorlatinib as a First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer: A Cost-Effectiveness Analysis in Greece
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03617-3&doi=10.1016/j.jval.2023.09.487
First page :
Section Title :
Open access? :
No
Section Order :
12512